^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

Published date:
11/01/2021
Excerpt:
Among 21 human SCLC cell lines...cell lines with high expression of Schlafen-11 (SLFN11) protein, a promising biomarker of response to other DNA damaging agents (e.g., chemotherapy, PARP inhibitors), were more sensitive to single-agent lurbinectedin (FC =3.2, P=0.005). SLFN11 was validated as a biomarker of sensitivity to lurbinectedin....As shown in Figure 1C, cell lines with higher SLFN11 expression (bimodal separation by RPPA) were significantly more sensitive to lurbinectedin (P=0.006, FC=3.26)…. In DMS79 xenografts that have high SLFN11 expression, lurbinectedin treatment significantly reduced tumor growth as compared to vehicle (Figure 1G).
DOI:
doi: 10.21037/tlcr-21-437